Ferroptosis‐Enhanced Cancer Immunity by a Ferrocene‐Appended Iridium(III) Diphosphine Complex

2021 ◽  
Author(s):  
Wen-Jin Wang ◽  
Yu-Yi Ling ◽  
Yan-Mei Zhong ◽  
Zhi-Yuan Li ◽  
Cai-Ping Tan ◽  
...  
Keyword(s):  
Cancer Immunity

Therapeutic Perspectives of Food Bioactive Peptides: A Mini Review

2019 ◽  
Vol 26 (9) ◽  
pp. 664-675
Author(s):  
Sulochana Priya
Keyword(s):  
Bioactive Peptides ◽  
Marine Organism ◽  
Biological Effects ◽  
Amide Bond ◽  
Therapeutic Effects ◽  
Specific Sequence ◽  
The Past ◽  
Cancer Immunity ◽  
Microbial Infections ◽  
Diverse Origin

Bioactive peptides are short chain of amino acids (usually 2-20) that are linked by amide bond in a specific sequence which have some biological effects in animals or humans. These can be of diverse origin like plant, animal, fish, microbe, marine organism or even synthetic. They are successfully used in the management of many diseases. In recent years increased attention has been raised for its effects and mechanism of action in various disease conditions like cancer, immunity, cardiovascular disease, hypertension, inflammation, diabetes, microbial infections etc. Bioactive peptides are more bioavailable and less allergenic when compared to total proteins. Food derived bioactive peptides have health benefits and its demand has increased tremendously over the past decade. This review gives a view on last two years research on potential bioactive peptides derived from food which have significant therapeutic effects.

scholarly journals Human Ferritin Platform and Its Optimized Structures to Enhance Anti‐Cancer Immunity

2020 ◽  
pp. 2000208
Author(s):  
Bo‐Ram Lee ◽  
Hyo‐Jung Lee ◽  
June Huh ◽  
Chul Joo Yoon ◽  
Se Jin Oh ◽  
...  
Keyword(s):  
Cancer Immunity ◽  
Anti Cancer ◽  
Human Ferritin

scholarly journals Double-edged effects of interferons on the regulation of cancer-immunity cycle

2021 ◽  
Vol 10 (1) ◽  
pp. 1929005
Author(s):  
Xiao Zhang ◽  
Song Wang ◽  
Yuanyuan Zhu ◽  
Minghui Zhang ◽  
Yan Zhao ◽  
...  
Keyword(s):  
Cancer Immunity

scholarly journals NF-κB in Cancer Immunity: Friend or Foe?

Cells ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 355
Author(s):  
Guilhem Lalle ◽  
Julie Twardowski ◽  
Yenkel Grinberg-Bleyer
Keyword(s):  
Immune Responses ◽  
Therapeutic Potential ◽  
Cell Types ◽  
Transcriptional Activators ◽  
New Class ◽  
Complex Interactions ◽  
Cancer Immunity ◽  
Distinct Cell ◽  
Cancer Initiation ◽  
Cancer Outcome

The emergence of immunotherapies has definitely proven the tight relationship between malignant and immune cells, its impact on cancer outcome and its therapeutic potential. In this context, it is undoubtedly critical to decipher the transcriptional regulation of these complex interactions. Following early observations demonstrating the roles of NF-κB in cancer initiation and progression, a series of studies converge to establish NF-κB as a master regulator of immune responses to cancer. Importantly, NF-κB is a family of transcriptional activators and repressors that can act at different stages of cancer immunity. In this review, we provide an overview of the selective cell-intrinsic contributions of NF-κB to the distinct cell types that compose the tumor immune environment. We also propose a new view of NF-κB targeting drugs as a new class of immunotherapies for cancer.

scholarly journals Differential effects of zoledronic acid and oestrogen on anti-cancer immunity

Bone Reports ◽  
2021 ◽  
Vol 14 ◽  
pp. 101024
Author(s):  
Chris George ◽  
Diane Lefley ◽  
Victor Canuas-Landero ◽  
Claudia Tulotta ◽  
Hannah Corness ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Differential Effects ◽  
Cancer Immunity ◽  
Anti Cancer

scholarly journals Symphony of nanomaterials and immunotherapy based on the cancer‒immunity cycle

2021 ◽  
Author(s):  
Qianqian Li ◽  
Zhaoqing Shi ◽  
Fan Zhang ◽  
Weiwei Zeng ◽  
Dunwan Zhu ◽  
...  
Keyword(s):  
Cancer Immunity

scholarly journals Pan-cancer characterization of lncRNA modifiers of immune microenvironment reveals clinically distinct de novo tumor subtypes

2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Zicheng Zhang ◽  
Congcong Yan ◽  
Ke Li ◽  
Siqi Bao ◽  
Lei Li ◽  
...  
Keyword(s):  
Noncoding Rna ◽  
Immune Cell ◽  
De Novo ◽  
Solid Cancer ◽  
Immune Microenvironment ◽  
Cancer Subtypes ◽  
Tumor Subtypes ◽  
Cancer Immunity ◽  
Systems Immunology ◽  
Pan Cancer

AbstractThe emerging field of long noncoding RNA (lncRNA)-immunity has provided a new perspective on cancer immunity and immunotherapies. The lncRNA modifiers of infiltrating immune cells in the tumor immune microenvironment (TIME) and their impact on tumor behavior and disease prognosis remain largely uncharacterized. In the present study, a systems immunology framework integrating the noncoding transcriptome and immunogenomics profiles of 9549 tumor samples across 30 solid cancer types was used, and 36 lncRNAs were identified as modifier candidates underlying immune cell infiltration in the TIME at the pan-cancer level. These TIME lncRNA modifiers (TIL-lncRNAs) were able to subclassify various tumors into three de novo pan-cancer subtypes characterized by distinct immunological features, biological behaviors, and disease prognoses. Finally, a TIL-lncRNA-derived immune state index (TISI) that was reflective of immunological and oncogenic states but also predictive of patients’ prognosis was proposed. Furthermore, the TISI provided additional prognostic value for existing tumor immunological and molecular subtypes. By applying the TISI to tumors from different clinical immunotherapy cohorts, the TISI was found to be significantly negatively correlated with immune-checkpoint genes and to have the ability to predict the effectiveness of immunotherapy. In conclusion, the present study provided comprehensive resources and insights for future functional and mechanistic studies on lncRNA-mediated cancer immunity and highlighted the potential of the clinical application of lncRNA-based immunotherapeutic strategies in precision immunotherapy.

Sign in / Sign up

Export Citation Format

Share Document